<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630860</url>
  </required_header>
  <id_info>
    <org_study_id>LY03003/CT-CHN-106</org_study_id>
    <nct_id>NCT04630860</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD</brief_title>
  <official_title>A Randomized, Open-label, Multiple Ascending Dose Study in Patients With Advanced-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the pharmacokinetics and safety of LY03003 in patients with&#xD;
      advanced-stage PD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>From Titration Period to Day 50 of Dose Maintenance Period</time_frame>
    <description>Blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax ,ss</measure>
    <time_frame>From Titration Period to Day 50 of Dose Maintenance Period</time_frame>
    <description>Peak concentration</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>56mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>84mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>112mg dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY03003</intervention_name>
    <description>Rotigotine,extended-release microspheres</description>
    <arm_group_label>112mg dose group</arm_group_label>
    <arm_group_label>56mg dose group</arm_group_label>
    <arm_group_label>84mg dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent must be given to the study and written informed consent must be&#xD;
             voluntarily signed, good communication with the investigator and compliance with all&#xD;
             requirements of the clinical trial (planned visits, laboratory tests and other test&#xD;
             procedures);&#xD;
&#xD;
          2. During screening, subjects are 18-80 years old (including boundary value), regardless&#xD;
             of gender;&#xD;
&#xD;
          3. Male subjects shall weigh no less than 50kg and female subjects shall weigh no less&#xD;
             than 45kg. Body mass index within the range of 19~30kg/m2 (including critical value);&#xD;
&#xD;
          4. Meet the diagnostic criteria of MDS for primary Parkinson's disease with sick time&#xD;
             more than 3 years. The diagnosis is based on the main symptoms-motor retardation, plus&#xD;
             at least one of the following symptoms: quiescence tremor, myotonia, and no other&#xD;
             known or suspected causes of Parkinson's disease;&#xD;
&#xD;
          5. In the &quot;on&quot; state, subjects' HOehn-YahR rating is from level 2 to level 3;&#xD;
&#xD;
          6. A concise Mental State Scale (MMSE) score ≥25;&#xD;
&#xD;
          7. A steady dose of Levodopa (either monotherapy or in combination with&#xD;
             benserazide/carbidopa/carbidopa) shall be administered at least 2 times a day for a&#xD;
             minimum of 28 days prior to baseline;&#xD;
&#xD;
          8. if you are accept anticholinergic drugs (such as benzalkonium tropic, benzene hai suo,&#xD;
             diethyl promethazine, its organism and than pp board), monoamine oxidase B (MAO B)&#xD;
             inhibitors (e.g., company to gillan, LeiSha gillan) and/or N - methyl - d - aspartate&#xD;
             (NMDA) antagonist (such as amantadine) treatment, must be accepted before baseline at&#xD;
             least 28 days, stable doses and during the study period to maintain the therapeutic&#xD;
             dose;&#xD;
&#xD;
          9. Women of childbearing age (those who do not meet any of the following conditions:&#xD;
             menstrual stop ≥ 12 months; Or had undergone hysterectomy or bilateral oophorectomy;&#xD;
             (or with medically confirmed ovarian failure) or male subjects agree to use reliable&#xD;
             contraceptives (oral contraceptives, condom use, abstinence, etc.) throughout the&#xD;
             study period (screening visits until the end of the study), and pregnancy tests for&#xD;
             women of childbearing age are negative at screening and baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with atypical Parkinson's disease caused by the use of drugs (such as&#xD;
             methoxylopramine, flunarizine), hereditary metabolic diseases of the nervous system&#xD;
             (such as Wilson's disease), encephalitis, cerebrovascular diseases or degenerative&#xD;
             diseases (such as progressive supravuclear palsy);&#xD;
&#xD;
          2. The author had a history of epilepsy, or had a history of stroke or transient ischemic&#xD;
             stroke within 1 year before the visit;&#xD;
&#xD;
          3. Dementia, active mental illness or hallucinations, major depression;&#xD;
&#xD;
          4. Those with a history of suicide attempts (including actual attempts, attempts&#xD;
             interrupted or failed) or suicidal ideation in the past 6 months, defined as those who&#xD;
             answered &quot;yes&quot; to question 4 or 5 on the Columbia-Suicide Severity Rating Scale&#xD;
             (C-SSRS) at the time of screening;&#xD;
&#xD;
          5. Patients with a history of narcolepsy;&#xD;
&#xD;
          6. There is impulse control disorder (ICD) evidence;&#xD;
&#xD;
          7. Uncontrolled or severe cardiovascular disease, including New York Heart Association&#xD;
             (NYHA) class II or higher congestive heart failure, unstable angina, myocardial&#xD;
             infarction, or the presence of arrhythmia requiring treatment during screening;&#xD;
&#xD;
          8. Patients with malignant tumors within 5 years before screening, except for cervical&#xD;
             carcinoma in situ, basal cell or squamous cell carcinoma of the skin, local prostate&#xD;
             cancer after radical surgery, and intraductal carcinoma in situ after radical surgery;&#xD;
&#xD;
          9. History of pallidotomy, thalamic lesion, deep brain stimulation or fetal tissue&#xD;
             transplantation;&#xD;
&#xD;
         10. received cabergoline or bromocriptine within 15 days before baseline, or received&#xD;
             other dopamine agonists within 7 days before baseline;&#xD;
&#xD;
         11. Patients received any of the following drugs within 28 days before baseline:&#xD;
             α-methyldopa, metoclopramide, flunarizine, reserpine, antipsychotics, monoamine&#xD;
             oxidase A (MAO-A) inhibitors, methylphenidate, amphetamine, cloth, etc.;&#xD;
&#xD;
         12. Currently receiving treatment for central nervous system diseases (e.g., sedatives,&#xD;
             hypnotics, antidepressants, anxiolytics), unless the dose is stable for at least 28&#xD;
             days before baseline, and the treatment dose is maintained during the study period;&#xD;
&#xD;
         13. Known history of intolerance/allergy to the following antiemetics: domperidone,&#xD;
             trimethoxybenzamide, ondansetron, tropisetron, granisetron, and glycopyrrolate;&#xD;
&#xD;
         14. Screening or baseline, ECG examination QTc &gt; 450 milliseconds (male) or &gt; 460&#xD;
             milliseconds (female) or other abnormalities judged by the investigator have clinical&#xD;
             significance;&#xD;
&#xD;
         15. History of orthostatic hypotension; or systolic blood pressure (SBP) decreased by ≥ 20&#xD;
             mmHg or diastolic blood pressure (DBP) decreased by ≥ 10 mmHg when changing from the&#xD;
             decubitus position to the upright position for 1 or 3 minutes at screening or&#xD;
             baseline; or systolic pressure &lt; 105 mmHg at screening or baseline;&#xD;
&#xD;
         16. Clinically significant abnormal liver function, defined as total bilirubin &gt; 1.5 times&#xD;
             the upper limit of the reference range or alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) &gt; 2 times the upper limit of the reference range;&#xD;
&#xD;
         17. Clinically significant renal dysfunction (serum creatinine &gt; 2.0 mg/dL or &gt; 177&#xD;
             umol/L]);&#xD;
&#xD;
         18. Any test result of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV)&#xD;
             antibody, human immunodeficiency virus (HIV) antibody is positive;&#xD;
&#xD;
         19. Smokers, alcoholics:&#xD;
&#xD;
             A) Smoking is defined as: an average daily smoking of ≥ 5 cigarettes within 3 months&#xD;
             before screening; B) Alcohol abuse is defined as: drinking more than 14 units of&#xD;
             alcohol per week (1 unit = 350 mL of beer, or 45 mL of liquor, or 150 mL of wine)&#xD;
             within 3 months before screening.&#xD;
&#xD;
         20. Pregnant or lactating women;&#xD;
&#xD;
         21. Allergic constitution (allergic to two or more drugs or food) or known to be allergic&#xD;
             to rotigotine or rotigotine microsphere preparation ingredients;&#xD;
&#xD;
         22. Previous use of rotigotine-containing preparations can not tolerate or poor efficacy;&#xD;
&#xD;
         23. Participated in other drug clinical trials within 3 months before screening;&#xD;
&#xD;
         24. Other clinically significant medical conditions, mental conditions or laboratory&#xD;
             abnormalities that may interfere with the ability of the subject to participate in&#xD;
             this study as judged by the investigator;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuren Guo</last_name>
    <phone>13501029003</phone>
    <email>guoshuren@luye.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biao Chen</last_name>
      <phone>13501086287</phone>
      <email>pbchan90@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>parkinson disease</keyword>
  <keyword>LY03003</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

